231 related articles for article (PubMed ID: 38637419)
1. The RAS oncogene in brain tumors and the involvement of let-7 microRNA.
Messina S
Mol Biol Rep; 2024 Apr; 51(1):531. PubMed ID: 38637419
[TBL] [Abstract][Full Text] [Related]
2. Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.
Wang XR; Luo H; Li HL; Cao L; Wang XF; Yan W; Wang YY; Zhang JX; Jiang T; Kang CS; Liu N; You YP;
Neuro Oncol; 2013 Nov; 15(11):1491-501. PubMed ID: 24092860
[TBL] [Abstract][Full Text] [Related]
3. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
Ngalame NN; Tokar EJ; Person RJ; Xu Y; Waalkes MP
Toxicol Sci; 2014 Apr; 138(2):268-77. PubMed ID: 24431212
[TBL] [Abstract][Full Text] [Related]
4. Let-7 microRNA inhibits the proliferation of human glioblastoma cells.
Lee ST; Chu K; Oh HJ; Im WS; Lim JY; Kim SK; Park CK; Jung KH; Lee SK; Kim M; Roh JK
J Neurooncol; 2011 Mar; 102(1):19-24. PubMed ID: 20607356
[TBL] [Abstract][Full Text] [Related]
5. The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells.
Wang X; Zhao J; Huang J; Tang H; Yu S; Chen Y
Biochem Biophys Res Commun; 2012 Aug; 425(1):51-7. PubMed ID: 22820191
[TBL] [Abstract][Full Text] [Related]
6. The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy.
Wang G; Wang J; Zhao H; Wang J; Tony To SS
Arch Biochem Biophys; 2015 Aug; 580():84-92. PubMed ID: 26151775
[TBL] [Abstract][Full Text] [Related]
7. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
8. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice.
He XY; Chen JX; Zhang Z; Li CL; Peng QL; Peng HM
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1023-8. PubMed ID: 20033209
[TBL] [Abstract][Full Text] [Related]
9. KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors.
Jiao LR; Frampton AE; Jacob J; Pellegrino L; Krell J; Giamas G; Tsim N; Vlavianos P; Cohen P; Ahmad R; Keller A; Habib NA; Stebbing J; Castellano L
PLoS One; 2012; 7(2):e32068. PubMed ID: 22384141
[TBL] [Abstract][Full Text] [Related]
11. Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer.
Long XB; Sun GB; Hu S; Liang GT; Wang N; Zhang XH; Cao PP; Zhen HT; Cui YH; Liu Z
Oncol Rep; 2009 Nov; 22(5):1189-95. PubMed ID: 19787239
[TBL] [Abstract][Full Text] [Related]
12. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
[TBL] [Abstract][Full Text] [Related]
13. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
[TBL] [Abstract][Full Text] [Related]
14. Loss of MYC and E-box3 binding contributes to defective MYC-mediated transcriptional suppression of human MC-let-7a-1~let-7d in glioblastoma.
Wang Z; Lin S; Zhang J; Xu Z; Xiang Y; Yao H; Ge L; Xie D; Kung HF; Lu G; Poon WS; Liu Q; Lin MC
Oncotarget; 2016 Aug; 7(35):56266-56278. PubMed ID: 27409345
[TBL] [Abstract][Full Text] [Related]
15. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
17. The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model.
García-Cruz R; Camats M; Calin GA; Liu CG; Volinia S; Taccioli C; Croce CM; Bach-Elias M
BMC Med Genet; 2015 Jul; 16():46. PubMed ID: 26138095
[TBL] [Abstract][Full Text] [Related]
18. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma.
Wang G; Wang JJ; Tang HM; To SS
Arch Biochem Biophys; 2015 Aug; 580():64-74. PubMed ID: 26142886
[TBL] [Abstract][Full Text] [Related]
19. Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer.
Wang M; Hu Y; Amatangelo MD; Stearns ME
Mol Cancer Res; 2011 Jan; 9(1):36-50. PubMed ID: 21148031
[TBL] [Abstract][Full Text] [Related]
20. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1.
Lulli V; Buccarelli M; Ilari R; Castellani G; De Dominicis C; Di Giamberardino A; D Alessandris QG; Giannetti S; Martini M; Stumpo V; Boe A; De Luca G; Biffoni M; Marziali G; Pallini R; Ricci-Vitiani L
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
